Skip to main content

ACR Award Winners (10.21.2022)

Oct 21, 2022 2:16 pm

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

  1. Vaccination Cut Long COVID Risk for Rheum Patients Patients with rheumatologic conditions who developed breakthrough COVID-19 infection after vax were less likely to suffer long-term symptoms than unvaxxed but otherwise similar patients, research said. https://t.co/XENKQUpxOO

  2. Spinal cord stimulation is a $2-3billion market, despite limited efficacy. A placebo controlled trial of spinal cord burst stimulation, in 50 pts w/ chr radicular pain after lumbar surgery, showed no significant benefit in back pain–related disability. https://t.co/aRN5sRbqFx

  3. Downstream revenues from Rheum? The Rheumatologist reports and impt reference showing for every $1 dollar office visit billed, $12.14 generated in downstream revenues (infusions, labs, surgery). Cognitive specialists are undervalued! https://t.co/YatkwrBCeQ

  4. Cross-sectional study of 291 PCPs shows that increased electronic health record (EHR) time was associated with a significantly greater liklihood of meeting patient target goals for Hgb-A1C, HTN control and breast cancer screening https://t.co/mLdoHM9N7O

  5. EMA CHMP issued a positive opinion on the safety of Filgotinib, a selective JAK1 inhibitor, based on testicular safety data from the MANTA & MANTA-RAy studies. Gilead withdrew filgotinib from US market w/ FDA concerns on testicular safety in 12/20 https://t.co/38xOWb1zJi

  6. Urine proteomics on 54 SLE pts in the Belimumab–Lupus Nephritis trial, compared responders (n 31) v non-responders (n 22), on BEL or SOC. Reduction in urinary CD163 was strongly associated with complete renal response @wk52 & CD23 @wk24 https://t.co/PrXaJq6h0E

  7. Do you renal Bx your #SLE pts? Study of 277 SLE pts w/ US-guided percutaneous renal bx showed bleeding complications post biopsy to be 19.9% (minor 13%; major 7%); risk higher w/ thrombocytopenia (OR 7.12)low eGFR (OR 3.5) https://t.co/vYYChuGdSN

  8. Co-administration of MTX with Folic Acid on the same day did not reduce efficacy compared to FA application one day after MTX. (based on AIA was induced in female Lewis rats) https://t.co/WBT5BOBPqz

  9. Large retrospective claims data analysis of 86 964 adults w/ severe obesity and NAFLD: comparing bariatric surgery (35%) to those with nonsurgical care. Bariatric surgery lowered the risk of CVD by 49% https://t.co/xEVVQVEX30

  10. Single center use IL-23 inhibitors (Guselkumab, Tildrakizumab, Risankizumab) in 80 PsA pts shows 1 yr survival 81%, w/ mean survival 61 wks (despite 95% Rx ≥1 prior biologics). 64% had PASI ≤2 at wks 12-17 and nearly 41% w/ PsA remission https://t.co/woDXhL44d5

  11. Tofacitinib in 15 pts w/ early diffuse skin Scleroderma. Tofa downregulated STAT3 (macrophages, DCs) & IFN (fibroblasts) & MYOC/CCL19 (adventitial fibroblasts); well tolerated & trend to improved mRSS scores (ns) https://t.co/givh5j3m9z

  12. Prevotella Immune Response in Both Pre-Clinical & Established RA 

  13. Arthritis Clinical Trials Comparison Grid Use this resource to keep track of your clinical trials and key information needed when communicating with patients about a drug study.

  14. ACR Announces 2022 Award Recipients

  15. Pregnancy Outcomes with Belimumab

  16. BEST OF RhAPP - Best of RhAPP Regional Summit Series: Advancing Rheumatic Disease Care in the Community. 10/29/22 Houston Texas

  17. #ACA - Ask Cush Anything. Record a Question or Comment  Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.

Disclosures
The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×